asikkk/iStock via Getty Images A transcatheter aortic valve replacement from Boston Scientific ( NYSE: BSX ) that is considered next-generation technology failed to meet its primary endpoint in a key trial. Results from the ACURATE IDE trial found that the ACURATE neo2 aortic valve had a composite.
Back to Health Page
